Get started
IPCA Laboratories LimitedIPCA Laboratories LimitedIPCA Laboratories Limited

IPCA Laboratories Limited

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IPCALAB chart


Full chart

IPCALAB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪334.65 B‬ INR
Dividend yield (indicated)
0.30%
Price to earnings Ratio (TTM)
43.00
Basic EPS (TTM)
30.70 INR
Net income (FY)
‪7.38 B‬ INR
Revenue (FY)
‪88.49 B‬ INR
Shares float
‪127.23 M‬
Beta (1Y)
0.66

Employees


Employees (FY)
‪23.24 K‬
Change (1Y)
+395 +1.73%
Revenue / Employee (1Y)
‪3.81 M‬ INR
Net income / Employee (1Y)
‪317.47 K‬ INR

About IPCA Laboratories Limited


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pranay Godha
Website
ipca.com
Headquarters
Mumbai
Founded
1949
ISIN
INE571A01038
FIGI
BBG000D4LR21
Ipca Laboratories Ltd. engages in the manufacturing, marketing, research, and development of pharmaceutical products. Its products include Hydroxychloroquine Sulphate, Artemether and Lumefantrine and Acceclofenac and its combinations. The company was founded on October 19, 1949 and is headquartered in Mumbai, India.

Check out other big names from the same industry as IPCALAB.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IPCALAB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IPCALAB is 1,320.10 INR — it has decreased by −0.02% in the past 24 hours. Watch IPCA Laboratories Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange IPCA Laboratories Limited stocks are traded under the ticker IPCALAB.
IPCALAB stock has fallen by −3.44% compared to the previous week, the month change is a −5.70% fall, over the last year IPCA Laboratories Limited has showed a −7.22% decrease.
We've gathered analysts' opinions on IPCA Laboratories Limited future price: according to them, IPCALAB price has a max estimate of 1,767.00 INR and a min estimate of 1,135.00 INR. Watch IPCALAB chart and read a more detailed IPCA Laboratories Limited stock forecast: see what analysts think of IPCA Laboratories Limited and suggest that you do with its stocks.
IPCALAB reached its all-time high on Jan 7, 2025 with the price of 1,755.90 INR, and its all-time low was 2.75 INR and was reached on Sep 17, 2001. View more price dynamics on IPCALAB chart.
See other stocks reaching their highest and lowest prices.
IPCALAB stock is 2.60% volatile and has beta coefficient of 0.66. Track IPCA Laboratories Limited stock price on the chart and check out the list of the most volatile stocks — is IPCA Laboratories Limited there?
Today IPCA Laboratories Limited has the market capitalization of ‪334.65 B‬, it has decreased by −1.37% over the last week.
Yes, you can track IPCA Laboratories Limited financials in yearly and quarterly reports right on TradingView.
IPCA Laboratories Limited is going to release the next earnings report on Nov 10, 2025. Keep track of upcoming events with our Earnings Calendar.
IPCALAB earnings for the last quarter are 9.19 INR per share, whereas the estimation was 9.07 INR resulting in a 1.36% surprise. The estimated earnings for the next quarter are 9.70 INR per share. See more details about IPCA Laboratories Limited earnings.
IPCA Laboratories Limited revenue for the last quarter amounts to ‪23.09 B‬ INR, despite the estimated figure of ‪23.17 B‬ INR. In the next quarter, revenue is expected to reach ‪24.34 B‬ INR.
IPCALAB net income for the last quarter is ‪2.33 B‬ INR, while the quarter before that showed ‪678.20 M‬ INR of net income which accounts for 243.87% change. Track more IPCA Laboratories Limited financial stats to get the full picture.
IPCA Laboratories Limited dividend yield was 0.27% in 2024, and payout ratio reached 13.76%. The year before the numbers were 0.32% and 18.54% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 9, 2025, the company has ‪23.24 K‬ employees. See our rating of the largest employees — is IPCA Laboratories Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IPCA Laboratories Limited EBITDA is ‪17.50 B‬ INR, and current EBITDA margin is 19.48%. See more stats in IPCA Laboratories Limited financial statements.
Like other stocks, IPCALAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IPCA Laboratories Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IPCA Laboratories Limited technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IPCA Laboratories Limited stock shows the neutral signal. See more of IPCA Laboratories Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.